NuCana to Showcase Findings on NUC-7738's Combined Effect with PD-1 Inhibitors at ESMO Congress 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 03 2025
0mins
Source: Globenewswire
NuCana's Presentation at ESMO Congress 2025: NuCana plc will present an abstract titled "Patient Derived Organoids Reveal Synergy Between NUC-7738 and PD-1 Inhibition in Renal Cell Cancer" at the ESMO Congress 2025 in Berlin, scheduled for October 19, 2025.
About NuCana's Drug Development: NuCana is focused on improving cancer treatment through its ProTide technology, with ongoing clinical studies for its drug candidates NUC-7738 and NUC-3373, aimed at enhancing the efficacy and safety of existing chemotherapy agents.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
